[Journal of Hepatocellular Carcinoma] Although prognosis is poor for patients with hepatocellular carcinoma (HCC), especially those with cirrhosis, a prolonged subclinical growth period offers a window of time for curative treatment. In this review, researchers discuss the current status of screening, and what can be done to improve its potential.
[Journal of Hepatocellular Carcinoma]
The Breakthrough Therapy designation was based on updated interim results from the multicenter, open-label, phase 1b KEYNOTE-524/Study 116 trial .
[Cancer Management and Research] The aim of this study was to establish a prognostic estimation of CHCs after resection (PECAR) score predicting recurrence on the basis of the clinicopathological data.
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
An analysis of results from the NHS and the HPFS showed that regular use of aspirin — standard-dose 325-mg tablets — reduced hepacellular carcinoma in a dose-dependent manner.
[Journal of Hepatocellular Carcinoma] A review of the manifestations, treatments, and challenges associated with hepatocellular cancer pain.
[Journal of Hepatocellular Carcinoma] In this case series, the authors present procedure and treatment specifics for 2 patients with HCV who developed HCC, and discuss the potential role of DAA therapy and immunosurveillance.
Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Patients with alcohol-related HCC displayed reduced OS when compared to patients with non-alcohol-related HCC.
